← Oncology Approval Tracker

FDA DECISION ·

Blenrep

belantamab mafodotin-blmf · GlaxoSmithKline

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

With bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least two prior lines that included a proteasome inhibitor and an immunomodulatory agent.

LAMPGEN ANALYSIS

Why it matters

The FDA approved a distinct BCMA-directed combination after withdrawal of the earlier single-agent indication.

What research teams should watch

Arrange REMS enrollment and timely eye examinations so corneal toxicity assessments inform each dosing decision.

PRIMARY RECORDS

Sources